



Beta Cell Preservation Work Group Monthly Meeting

March 3, 2026

Agenda

1. Welcome and updates
2. Promoting and using the white paper
3. Disseminating the white paper
 - ISPAD
 - ADA Sci Sessions and/or Breakthrough T1D Clinical & Research Congress
 - ATTD presentation
4. Update on measures

Thank you, Trevon!



- Trevon will be leaving his role at T1D Exchange next week.
- We thank him for his leadership in this project, the Screening & Monitoring, the BPA, the HEAL Committee, as well as an amazing QI coach and coordinator for HCL group.

Updates: new qualitative study: March-June 2026

Exploring Clinic Practices with Type 1 Diabetes Healthcare Professionals on Recruitment for Disease-Modifying Therapy Clinical Trials

Title: Exploring Clinic Practices with Type 1 Diabetes Healthcare Professionals on Recruitment for Disease-Modifying Therapy Clinical Trials

Project Purpose:

The purpose of this project is to understand how, when, and where people newly diagnosed with Stage 3 type 1 diabetes and their families learn about disease modifying therapy (DMT) clinical trials from within clinical care settings.

This project will examine structural, behavioral, and workflow-related factors that influence whether and how healthcare professionals (HCPs) discuss DMT clinical trials with patients in endocrine and diabetes clinics.

Specifically, this project aims to:

- Learn more about when and how patients and families are informed about clinical trials in clinic settings.
- Learn about who is discussing DMT clinical trials with patients.
- Document best practices from clinics that share information on clinical trials effectively.
- Identify barriers that HCPs have when sharing information on currently recruiting clinical trials with their patients.

Breakthrough T1D intends to use this information to develop HCP resources aimed at increasing clinical trial awareness and participant enrollment.

Deliverable	Estimated Timeline (Week of)
Kickoff meeting, to occur within three weeks of executed agreement	March 23, 2026
Study Protocol <ul style="list-style-type: none"> • Interview guide development, code book formation • IRB submission for focus groups with recruitment material approval 	April 6, 2026
Focus Group Recruitment <ul style="list-style-type: none"> • Conduct 3 focus groups, including HCPs, from 6 centers 	May 25, 2026
<ul style="list-style-type: none"> • Complete analysis with development of a table with key themes (brief report) 	
Survey Development <ul style="list-style-type: none"> • Draft survey and receive IRB approval 	June 29, 2026
Deliverable	Timeline (Week of)
Survey Analysis <ul style="list-style-type: none"> • Launch survey and collect responses • Data cleaning and analysis • Prepare data tables 	Aug 17, 2026
Final Report <ul style="list-style-type: none"> • Prepare a report with major quantitative and qualitative findings with recommendations for HCPs 	Sept 28, 2026
Abstract Submission <ul style="list-style-type: none"> • Prepare an abstract for submission at a major diabetes conference 	TBD
Manuscript 1 Draft <ul style="list-style-type: none"> • Deliver a complete first draft including text, tables/figures and references 	By 12/31/2026

T1D Exchange QI Collaborative Beta Cell Preservation White Paper




→ February 2026



Real World Beta Cell Preservation Throughout the Stages of Type 1 Diabetes:

→ A Clinical and Implementation Framework from the T1D Exchange Quality Improvement Collaborative Beta Cell Preservation Working Group.

Download the White Paper:



Direct link to the white paper

- <https://t1dx-qi.t1dexchange.org/wp-content/uploads/2026/03/Real-World-Beta-Cell-Preservation-Throughout-the-Stages-of-Type-1-Diabetes.pdf>
- Please use and share the PDF link yourself and share with members of your team
- Use the QR code/slide to share white paper with external colleagues and for presentations

ISPAD Submission

- November 4-7th in Rio de Janeiro, Brazil
- Abstract submission deadline: April 22, 2026

ADA Scientific Sessions

- 2027 Scientific Sessions.
- Walter E. Washington Convention Center Washington, D.C.. **June 18-21, 2027**
- Symposia submission: May-June 2026??

Breakthrough T1D

- Clinical & Research Congress
- Friday, October 9, to Sunday, October 11, 2026, in Philadelphia, PA
- **Abstract submission deadline: April 15, 2026**

ATTD Presentation

Measures Update

Measures discussion- 2/28/2026

- Prioritizing a limited number of measures for 2026-2027

Key measures

- Screening (**date**, location of screening, **type of assay**, result, staging, staging dx date)
 - Which autoantibodies
 - Screening result (binary)
 - Therapy prescribed; therapy accepted or declined; therapy completed or partially completed; therapy side effects
 - C-peptide: group said need guidance
-
- Group discussed value of using the Texas Children's flowsheet. Dan will have available in the Epic Turbo Package

Measures

Category	Metric	Notes
Screening and Baseline	Autoantibodies <ul style="list-style-type: none"> • Method* • Age at screening* • Dates Setting (research / clinic)* Other autoimmunity* Source of Referral* DKA at Stage 3 diagnosis*	Dates for stage 1, 2, 3 Family history or autoimmunity
Therapies	Therapy (yes/no) <ul style="list-style-type: none"> • Timing of discussion Type of Therapy* Timing related to Stage 3 diagnosis* Related labs*	Reason declined if No Infections, CBC/CMP

Measures

	<p>Related labs*</p> <p>Protocol</p> <ul style="list-style-type: none"> • Protocol used, any deviation • Inpatient vs home vs hybrid • Age at treatment • Side effects 	<p>Infections, CBC/CRP</p>
Beta Cell	<p>C-peptide</p> <p>Total Daily Dose of Insulin* (units/kg/day)</p> <p>Insulin dose adjusted HbA1c *</p>	<p>MMTT vs random vs after a home meal; standardize <0.25 units/kg/day</p> <p>HbA1c + (4*TDD)</p>
Immunologic	<p>Autoantibody number and type*</p> <p>Repeat testing</p>	



Questions/Comments



T1D

Exchange